Triple negative breast cancer (TNBC) is a highly aggressive subtype of breast cancer (BC), with a poor prognosis with currently used therapies, and thus represents an unmet therapeutic challenge. Lack of molecular targets (i.e. ER, PR, HER2) and significant genetic heterogeneity are the major reasons contributing to early relapse and high mortality rates. Numerous studies have indicated that microRNAs (miRs) have an important role in BC progression, invasion, angiogenesis, and metastasis. We analyzed miRNA expression profiles of BC patient data bases and identified that miR-484 is highly upregulated in all subtypes of BC patients, with the highest expression in TNBC patients. miR-484 was found to be associated with significantly shorter patient survival, while inhibition of miR-484 in TNBC cells led to significant reduction of cell proliferation, motility and invasion, and induced cell cycle arrest and apoptosis. Furthermore, we found that miR-484 is inversely correlated with levels of HOXA5 in patients’ tumors and demonstrated that miR-484 directly binds to the 3¢-untranslated region (3¢-UTR) of HOXA5 mRNA to suppress its expression. Moreover, HOXA5 over-expression recapitulated the effects of miR-484 inhibition. In vivo therapeutic targeting of miR-484 by systemic administration of anti-miR-484 nanoparticles significantly induced HOXA5 expression and suppressed tumor growth and progression in orthotopic xenograft mouse models of TNBC. Thus, our findings provide new insights about the oncogenic role of miR-484 and suggest that miR-484 represents a novel therapeutic target in TNBC.
","abstract_html":"<p>Triple negative breast cancer (TNBC) is a highly aggressive subtype of breast cancer (BC), with a poor prognosis with currently used therapies, and thus represents an unmet therapeutic challenge. Lack of molecular targets (i.e. ER, PR, HER2) and significant genetic heterogeneity are the major reasons contributing to early relapse and high mortality rates. Numerous studies have indicated that microRNAs (miRs) have an important role in BC progression, invasion, angiogenesis, and metastasis. We analyzed miRNA expression profiles of BC patient data bases and identified that miR-484 is highly upregulated in all subtypes of BC patients, with the highest expression in TNBC patients. miR-484 was found to be associated with significantly shorter patient survival, while inhibition of miR-484 in TNBC cells led to significant reduction of cell proliferation, motility and invasion, and induced cell cycle arrest and apoptosis. Furthermore, we found that miR-484 is inversely correlated with levels of <em>HOXA5</em> in patients’ tumors and demonstrated that miR-484 directly binds to the 3¢-untranslated region (3¢-UTR) of <em>HOXA5 </em>mRNA to suppress its expression. Moreover, HOXA5 over-expression recapitulated the effects of miR-484 inhibition. <em>In vivo</em> therapeutic targeting of miR-484 by systemic administration of anti-miR-484 nanoparticles significantly induced HOXA5 expression and suppressed tumor growth and progression in orthotopic xenograft mouse models of TNBC. Thus, our findings provide new insights about the oncogenic role of miR-484 and suggest that miR-484 represents a novel therapeutic target in TNBC.</p>","abstract_has_math":false,"creators":["Kabil, Nashwa","0000-0002-5413-849X
"],"institution":null,"degree_name":"Doctor of Philosophy (PhD)","degree_level":"Dissertation (PhD)","degree_discipline":null,"degree_department":null,"school":null,"contributors":["Bulent Ozpolat M.D. Ph.D","Gabriel Lopez-Berestein M.D.","George A. Calin M.D. Ph.D"],"advisors":[],"committee_chairs":[],"committee_members":[],"year":2018,"date_issued":"2018-08-01T07:00:00Z","date_published":"2018-08-01T07:00:00Z","updated_at":"2026-07-24T05:48:47Z","subjects":["miRNA","miR-484","Triple Negative Breast Cancer","HOXA5","Medicine and Health Sciences"],"languages":[],"rights":[],"rights_urls":[],"identifier_entries":[]},"links":{"outbound_url":"https://digitalcommons.library.tmc.edu/utgsbs_dissertations/897","outbound_label":"Repository record","outbound_source":"dc:identifier"},"metadata_groups":[{"id":"people","label":"People","entries":[{"key":"dc:contributor","label":"Contributor","values":["Bulent Ozpolat M.D. Ph.D","Gabriel Lopez-Berestein M.D.","George A. Calin M.D. Ph.D"]},{"key":"dc:creator","label":"Author","values":["Kabil, Nashwa","0000-0002-5413-849X
"]}]},{"id":"academic_context","label":"Academic Context","entries":[{"key":"dc:date.available","label":"Dc Date Available","values":["2019-08-15T07:00:00Z"]},{"key":"thesis:degree_level","label":"Degree Level","values":["Dissertation (PhD)"]},{"key":"thesis:degree_name","label":"Degree Name","values":["Doctor of Philosophy (PhD)"]}]},{"id":"subjects_keywords","label":"Subjects and Keywords","entries":[{"key":"dc:subject","label":"Dc Subject","values":["miRNA","miR-484","Triple Negative Breast Cancer","HOXA5","Medicine and Health Sciences"]}]},{"id":"identifiers","label":"Identifiers","entries":[{"key":"dc:identifier","label":"Identifier","values":["https://digitalcommons.library.tmc.edu/utgsbs_dissertations/897"]}]},{"id":"additional","label":"Additional Metadata","entries":[{"key":"dc:description.abstract","label":"Abstract","values":["Triple negative breast cancer (TNBC) is a highly aggressive subtype of breast cancer (BC), with a poor prognosis with currently used therapies, and thus represents an unmet therapeutic challenge. Lack of molecular targets (i.e. ER, PR, HER2) and significant genetic heterogeneity are the major reasons contributing to early relapse and high mortality rates. Numerous studies have indicated that microRNAs (miRs) have an important role in BC progression, invasion, angiogenesis, and metastasis. We analyzed miRNA expression profiles of BC patient data bases and identified that miR-484 is highly upregulated in all subtypes of BC patients, with the highest expression in TNBC patients. miR-484 was found to be associated with significantly shorter patient survival, while inhibition of miR-484 in TNBC cells led to significant reduction of cell proliferation, motility and invasion, and induced cell cycle arrest and apoptosis. Furthermore, we found that miR-484 is inversely correlated with levels of HOXA5 in patients’ tumors and demonstrated that miR-484 directly binds to the 3¢-untranslated region (3¢-UTR) of HOXA5 mRNA to suppress its expression. Moreover, HOXA5 over-expression recapitulated the effects of miR-484 inhibition. In vivo therapeutic targeting of miR-484 by systemic administration of anti-miR-484 nanoparticles significantly induced HOXA5 expression and suppressed tumor growth and progression in orthotopic xenograft mouse models of TNBC. Thus, our findings provide new insights about the oncogenic role of miR-484 and suggest that miR-484 represents a novel therapeutic target in TNBC.
"]},{"key":"dc:title","label":"Title","values":["Mir-484 Functions As An Onco-Mir In Triple Negative Breast Cancer"]}]}],"canonical_facts":{"dc:contributor":["Bulent Ozpolat M.D. Ph.D","Gabriel Lopez-Berestein M.D.","George A. Calin M.D. Ph.D"],"dc:creator":["Kabil, Nashwa","0000-0002-5413-849X
"],"dc:date.available":["2019-08-15T07:00:00Z"],"dc:description.abstract":["Triple negative breast cancer (TNBC) is a highly aggressive subtype of breast cancer (BC), with a poor prognosis with currently used therapies, and thus represents an unmet therapeutic challenge. Lack of molecular targets (i.e. ER, PR, HER2) and significant genetic heterogeneity are the major reasons contributing to early relapse and high mortality rates. Numerous studies have indicated that microRNAs (miRs) have an important role in BC progression, invasion, angiogenesis, and metastasis. We analyzed miRNA expression profiles of BC patient data bases and identified that miR-484 is highly upregulated in all subtypes of BC patients, with the highest expression in TNBC patients. miR-484 was found to be associated with significantly shorter patient survival, while inhibition of miR-484 in TNBC cells led to significant reduction of cell proliferation, motility and invasion, and induced cell cycle arrest and apoptosis. Furthermore, we found that miR-484 is inversely correlated with levels of HOXA5 in patients’ tumors and demonstrated that miR-484 directly binds to the 3¢-untranslated region (3¢-UTR) of HOXA5 mRNA to suppress its expression. Moreover, HOXA5 over-expression recapitulated the effects of miR-484 inhibition. In vivo therapeutic targeting of miR-484 by systemic administration of anti-miR-484 nanoparticles significantly induced HOXA5 expression and suppressed tumor growth and progression in orthotopic xenograft mouse models of TNBC. Thus, our findings provide new insights about the oncogenic role of miR-484 and suggest that miR-484 represents a novel therapeutic target in TNBC.
"],"dc:identifier":["https://digitalcommons.library.tmc.edu/utgsbs_dissertations/897"],"dc:subject":["miRNA","miR-484","Triple Negative Breast Cancer","HOXA5","Medicine and Health Sciences"],"dc:title":["Mir-484 Functions As An Onco-Mir In Triple Negative Breast Cancer"],"thesis:degree_level":["Dissertation (PhD)"],"thesis:degree_name":["Doctor of Philosophy (PhD)"]},"updated_at":"2026-07-24T05:48:47Z"}